Bristol Gears Up For Orencia Launch With Creation Of Immunoscience Unit

Bristol-Myers Squibb has created an immunoscience business unit to support the upcoming launch of Orencia (abatacept) for rheumatoid arthritis, U.S. Pharmaceuticals President Anthony Hooper said